Skip to main content
Annals of the American Thoracic Society logoLink to Annals of the American Thoracic Society
. 2020 Nov;17(11):1476–1479. doi: 10.1513/AnnalsATS.202002-140CC

An Uncommon Cause of Bronchial Obstruction

John W Frey 1, Charles D Bengtson 1, Nirmal K Veeramachaneni 2, Kyle R Brownback 1,
PMCID: PMC7640715  PMID: 33124907

Case Vignette

A 72-year-old woman presented to our institution with fevers and cough. Her history was remarkable for stage IA adenocarcinoma of the right lung for which she had undergone wedge resection of the right lower lobe and right middle lobe 4 years before presentation. She subsequently had recurrence in the right infrahilar region for which she was treated with stereotactic body radiation therapy for a total of 50 Gy over five fractions, after being deemed a poor surgical candidate. Following radiation therapy, she was diagnosed with Mycobacterium avium complex (MAC), isolated via bronchial wash from the right bronchus intermedius (BI). She was actively being treated with rifampin, azithromycin, and ethambutol for 6 months at the time of presentation, with follow-up sputum cultures that were negative for growth.

At presentation, the patient’s vital signs were grossly normal with an oxygen saturation of 96% on room air. Physical exam was remarkable for decreased breath sounds on the right. Admission labs included a normal complete blood count and comprehensive metabolic panel. A computed tomographic angiography of the chest demonstrated increased right perihilar and infrahilar tissue fullness with occlusion of the BI in close proximity to the right pulmonary artery as well as patchy nodular opacities in the right lower lobe (Figures 1A and 1B). Empiric treatment for pneumonia was initiated, including piperacillin–tazobactam and levofloxacin. Bronchoscopy was subsequently performed. Upon entering the right mainstem bronchus, there was extensive fibropurulent material obstructing the orifice of the BI (Figure 1C). After debridement with forceps, the area was traversed. The pulmonary artery was then observed protruding through the medial wall of the BI (Figure 1D; see Video 1, showing pulsatile mass in BI).

Figure 1.

Figure 1.

(A and B) Computed tomographic angiography of the chest demonstrating increased right perihilar and infrahilar tissue fullness with occlusion of the bronchus intermedius (BI) in close proximity to the right pulmonary artery as well as patchy nodular opacities in the right lower lobe. Bronchoscopic images showing (C) orifice of BI with fibropurulent material before debridement and (D) debrided BI orifice with pulsatile mass as outlined in yellow. The arrow is indicating the pulmonary artery.

Video 1.

Download video file (23MB, mp4)

Bronchoscopy demonstrating evidence of the pulmonary artery protruding through the medial wall of the bronchus intermedius.

Questions

1. What is your differential diagnosis for this patient?

2. What are the next steps in management of this patient?

Clinical Reasoning and Diagnosis

The patient presented for fever and cough and was found to have an occluded BI on imaging. Given her history of lung cancer, radiation therapy, and MAC infection, we proceeded with bronchoscopy for further evaluation and found an area of bronchus that was eroded. Our main differential diagnosis for this finding included malignancy (primary vs. metastatic); radiation necrosis; and infectious pathogens including bacteria such as Staphylococcus and Klebsiella and fungi such as Aspergillus. Other, uncommon etiologies we considered less likely included autoimmune disorders such as relapsing polychondritis, sarcoidosis, granulomatosis with polyangiitis, and extraintestinal manifestation of inflammatory bowel disease.

Given the concern for erosion of the bronchus leading to herniation of the pulmonary artery, thoracic surgery consultation was obtained. The patient subsequently underwent right pneumonectomy with associated laparotomy for mobilization of omentum flap to cover the bronchial stump and hilum. Pathologic analysis of specimens from the pneumonectomy demonstrated necrotizing granulomas and the presence of fungal hyphae within the necrotic bronchial walls without evidence for tumor recurrence (Figures 2A–2C). Cultures demonstrated Aspergillus fumigatus. The patient was diagnosed with necrotizing pseudomembranous Aspergillus tracheobronchitis. Subsequent long-term treatment included micafungin followed by isavuconazole.

Figure 2.

Figure 2.

Pathologic analysis of pneumonectomy specimen. (A) Grocott stain demonstrating hyphae with acute angle branching characteristic of Aspergillus. Hematoxylin and eosin stain demonstrating (B) parenchymal necrotizing granulomas and (C) necrotizing inflammation within the airway wall.

Discussion

Invasive pulmonary aspergillosis can have a wide array of presentations including aspergilloma, angioinvasive disease, chronic necrotizing aspergillosis, and Aspergillus tracheobronchitis (ATB). ATB is an uncommon variant that accounts for approximately 7% of cases (1).

There are multiple risk factors for the development of ATB, many of which were present in this case. Malignancy and conditions related to immune compromise such as neutropenia, acquired immunodeficiency syndrome, and hematopoietic and solid organ transplant are common underlying conditions in ATB. Additionally, treatment with chronic corticosteroids, chemotherapy, radiation therapy, anatomic structural defects, and prior infection, including MAC, have all been reported as predisposing factors (2, 3).

Clinically, ATB can present with a wide range of symptoms such as cough, hemoptysis, wheezing, and shortness of breath, but patients may be asymptomatic (4). Imaging findings seen in ATB include thickening of the tracheobronchial wall as well as multifocal, irregular plaques. However, these findings are only observed in approximately 25% of cases (4). Because of nonspecific symptoms and imaging, bronchoscopy is required for the diagnosis of ATB.

Three subtypes of ATB have been described: pseudomembranous, ulcerative, and obstructive (5). Pseudomembranous tracheobronchitis is characterized by the formation of a pseudomembrane composed of hyphae, fibrin, and necrotic debris that fills the airway. In ulcerative tracheobronchitis, erosive lesions are seen in the cartilaginous tracheal rings. Obstructive tracheobronchitis is a noninvasive form characterized by growth of Aspergillus in the airways leading to endobronchial obstruction. More recently, a staging system has been proposed that includes the following: type I, superficial cartilage infiltrate; type II, erosion into the cartilage with airway destruction: type III, obstructive (pseudomembrane occluding >50% of airway); and type IV, mixed form (2). The prognosis of ATB depends on the type or stage and the patient’s immune status. Overall, ATB is fatal in approximately 40% of cases, and the rate is even higher when necrosis and pseudomembranes are present (6).

Once diagnosis of ATB is confirmed, pharmacologic therapy is typically the mainstay of treatment. The Infectious Diseases Society of America guidelines recommend treatment with voriconazole as first-line therapy (7). Alternate primary therapy options include isavuconazole and amphotericin B. In immunocompromised patients, the combination of voriconazole with an echinocandin may be beneficial. Minimum duration of therapy is typically 6–12 weeks, but extended treatment is often needed in the immunocompromised population. In some situations, depending on the location and extent of disease, surgery may be required, as it was in our case.

Historically, patients were not treated for central tumors (within 2 cm of the proximal bronchial tree) owing to grade 5 toxicity (8). Fatal hemorrhage from radiotherapy to the more central airway has been well described in the literature. Because this concept has been challenged by more recent reports, some patients, including ours, are offered stereotactic body radiation therapy to an area traditionally not felt to be suitable for radiotherapy. Unfortunately, our patient subsequently developed ATB in the radiation field with significant complications. Given the high risk of fatal hemorrhage related to exposure of the pulmonary artery in this situation, pneumonectomy was performed. Right pneumonectomy carries substantial risk of excess morbidity and mortality after neoadjuvant chemotherapy and conventional radiotherapy at 45 Gy (9). Unlike the left mainstem bronchus, which is buried within the mediastinum under the aortic arch, the right mainstem bronchus is exposed to a large pneumonectomy space, making it more prone to devascularization-related dehiscence. In our patient, risk for poor outcome due to the prior radiation was increased by the history of underlying infection. Soft tissue coverage has been described to mitigate these risks, and therefore, the omentum was chosen as the most robust choice to protect the right hilum from wound complications (10).

In summary, ATB is an infrequently encountered disease that is diagnosed by bronchoscopy. It is important to be aware of risk factors for development of ATB, several of which were present in our patient, and to aggressively treat when ATB is diagnosed, given the associated high mortality.

Answers

1. What is your differential diagnosis for this patient?

Malignancy (primary vs. metastatic); radiation necrosis; bacterial infection including Staphylococcus, Klebsiella, and MAC; and fungal infection such as Aspergillus. Other rarer etiologies to consider include autoimmune disorders such as relapsing polychondritis, sarcoidosis, granulomatosis with polyangiitis, and extraintestinal manifestations of inflammatory bowel disease.

2. What are the next steps in management of this patient?

Given the risk for fatal hemorrhage, thoracic surgery should be consulted for evaluation for pneumonectomy. Treatment with antifungal agents such as voriconazole, isavuconazole, or amphotericin B should be initiated.

Follow-Up

The patient underwent successful complex right pneumonectomy and was treated for 6 months with isavuconazole.

Insights

  • ATB can have a wide array of clinical presentations and imaging studies are usually nonspecific. Consequently, bronchoscopy is necessary to establish the diagnosis.

  • Following diagnosis, most cases of ATB can be managed medically with antifungal therapy, but surgical intervention may be necessary depending on the location and extent of disease.

Supplementary Material

Supplements
Author disclosures

Acknowledgments

Acknowledgment

We thank Dr. Rashna Madan for generously providing the pathologic specimen slides.

Footnotes

Supported in part by a National Institutes of Health Clinical and Translational Science Award (TL1TR002368) to the University of Kansas.

Author disclosures are available with the text of this article at www.atsjournals.org.

References

  • 1.Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625. doi: 10.1164/rccm.200401-093OC. [DOI] [PubMed] [Google Scholar]
  • 2.Wu N, Huang Y, Li Q, Bai C, Huang HD, Yao XP. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect. 2010;16:689–695. doi: 10.1111/j.1469-0691.2009.02923.x. [DOI] [PubMed] [Google Scholar]
  • 3.Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J. 2006;28:352–357. doi: 10.1183/09031936.06.00139005. [DOI] [PubMed] [Google Scholar]
  • 4.Fernández-Ruiz M, Silva JT, San-Juan R, de Dios B, García-Luján R, López-Medrano F, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012;91:261–273. doi: 10.1097/MD.0b013e31826c2ccf. [DOI] [PubMed] [Google Scholar]
  • 5.Denning DW. Commentary: unusual manifestations of aspergillosis. Thorax. 1995;50:812–813. doi: 10.1136/thx.50.7.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sayiner A, Kürşat S, Töz H, Duman S, Onal B, Tümbay E. Pseudomembranous necrotizing bronchial aspergillosis in a renal transplant recipient. Nephrol Dial Transplant. 1999;14:1784–1785. doi: 10.1093/ndt/14.7.1784. [DOI] [PubMed] [Google Scholar]
  • 7.Patterson TF, Thompson GR, III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60. doi: 10.1093/cid/ciw326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839. doi: 10.1200/JCO.2006.07.5937. [DOI] [PubMed] [Google Scholar]
  • 9.Albain KS, Swann RS, Rusch VW, Turrisi AT, III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386. doi: 10.1016/S0140-6736(09)60737-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Levashev YN, Akopov AL, Mosin IV. The possibilities of greater omentum usage in thoracic surgery. Eur J Cardiothorac Surg. 1999;15:465–468. doi: 10.1016/s1010-7940(99)00041-x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplements
Author disclosures

Articles from Annals of the American Thoracic Society are provided here courtesy of American Thoracic Society

RESOURCES